TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
In a phase III trial of adults with type 2 diabetes and increased cardiovascular risk, once-daily oral orforglipron met the prespecified noninferiority standard for major cardiovascular events compared with insulin glargine over a median of two years. The study did not establish cardiovascular benefit; a separate trial is planned to evaluate cardiovascular outcomes. Gastrointestinal side effects were more frequent with orforglipron.
Orforglipron, a once-daily oral GLP-1 medicine, met a prespecified cardiovascular safety standard compared with insulin glargine in adults with type 2 diabetes and increased cardiovascular risk, according to results from the phase III ACHIEVE-4 trial. The authors described orforglipron as a potential treatment option with established cardiovascular safety. The trial was not powered to establish cardiovascular superiority.
Over a median follow-up of two years, major adverse cardiovascular events occurred in 4.2% of participants assigned orforglipron and 5.0% assigned insulin glargine. The hazard ratio was 0.84, with a 95% confidence interval of 0.59 to 1.20. The trial met its statistical criterion for noninferiority; it was not statistically powered to test superiority on cardiovascular outcomes.
The trial randomized 2,749 adults in 16 countries to once-daily orforglipron or injectable insulin glargine. Participants had type 2 diabetes, a body mass index of at least 25, and increased cardiovascular risk; most had established cardiovascular disease. Researchers also reported better blood-sugar control and weight outcomes with orforglipron over 104 weeks, as well as a lower rate of clinically significant or severe hypoglycemia: 6.8%, compared with 19.2% for insulin glargine.
Gastrointestinal adverse events were more common with orforglipron, affecting 62.1% of participants versus 14.2% in the insulin group. They were the most common reason participants stopped orforglipron. The study also recorded a mean pulse-rate increase of 4.0 beats per minute at week 104 with orforglipron, compared with a 0.2-beat decrease with insulin glargine. Reported supraventricular tachyarrhythmias, including atrial fibrillation or flutter, occurred in 3.2% and 2.7%, respectively.
A Safety Result, Not Proof of Protection
For people with type 2 diabetes and cardiovascular risk, the result addresses whether orforglipron performed within the trial’s prespecified safety margin against an active treatment. That matters because medicines in the GLP-1 class are used to manage blood sugar and weight, while the source says more established peptide GLP-1 drugs have achieved proof of cardiovascular benefit and FDA approval for cardiovascular protection.
The distinction is central: ACHIEVE-4 supports cardiovascular safety relative to insulin glargine under the study conditions, but it does not demonstrate fewer heart attacks or strokes because of orforglipron. The reported event rates and hazard ratio should be read alongside the trial’s noninferiority design. The report also describes oral dosing, gastrointestinal side effects, and a pulse-rate increase with orforglipron.
How ACHIEVE-4 Fits the Evidence
Orforglipron is an oral, non-peptide GLP-1 receptor agonist. The report describes it as shelf-stable and usable without fasting or water restrictions, and says it has no time-of-day restrictions. The source says orforglipron is approved by the U.S. Food and Drug Administration for obesity and remains under development for diabetes.
Principal investigator Klara Klein of the University of North Carolina School of Medicine presented the results at the European Association for the Study of Diabetes meeting in Milan. The findings were published at the same time in The Lancet. The study enrolled people already taking one to three glucose-lowering medicines. Participants had type 2 diabetes and increased cardiovascular risk, and most had established cardiovascular disease.
The researchers noted limitations, including the trial’s open-label design and analyses of small subgroups without adjustment for multiple comparisons. The reported comparison was with insulin glargine, not a placebo or another GLP-1 medicine.
“These findings support orforglipron as a potential once-daily, oral treatment option with established cardiovascular safety in people with type 2 diabetes and increased cardiovascular risk.”
— ACHIEVE-4 study authors
Heart Benefit Remains Unproven
Whether orforglipron reduces cardiovascular events remains unknown. ACHIEVE-4 was not statistically powered to test superiority on cardiovascular outcomes. The trial enrolled a specific population, and the report describes analyses of small subgroups without adjustment for multiple comparisons.
The study authors reported differences in kidney-related measures, including lower albuminuria at week 52 and a slower estimated decline in kidney function compared with insulin glargine. These are trial findings, but this report does not establish that orforglipron prevents kidney disease progression. The study reported a pulse-rate increase through week 104 with orforglipron, as well as more gastrointestinal adverse events.
A Larger Outcomes Test Is Underway
The ongoing ATTAIN-Outcomes trial is powered for superiority in evaluating orforglipron against placebo on cardiovascular outcomes in people with established atherosclerotic cardiovascular disease or chronic kidney disease, with or without type 2 diabetes. The source report says that study is scheduled for completion in 2031. Its results will provide further evidence about whether orforglipron offers cardiovascular protection.
Orforglipron is also being studied for diabetes and other conditions. The authors concluded that ACHIEVE-4 findings support orforglipron as a potential treatment option with established cardiovascular safety. The trial also reported improvements in blood sugar and weight and a higher rate of gastrointestinal events compared with insulin glargine.
Key Questions
What did ACHIEVE-4 find about orforglipron and heart safety?
Major cardiovascular events occurred in 4.2% of participants taking orforglipron and 5.0% taking insulin glargine over a median of two years. Orforglipron met the trial’s prespecified noninferiority criterion.
Did the study prove orforglipron prevents heart attacks or strokes?
No. ACHIEVE-4 tested whether the drug met a cardiovascular safety benchmark against insulin glargine; it was not designed to prove cardiovascular benefit.
What side effects were reported?
Gastrointestinal events were reported in 62.1% of orforglipron participants and 14.2% of insulin glargine participants. They were the most common reason for stopping orforglipron. The study also found a mean pulse-rate increase with orforglipron at week 104.
When will researchers know if it offers heart protection?
The separate ATTAIN-Outcomes trial is designed to evaluate cardiovascular outcomes against placebo. The source report lists its expected completion as 2031.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
